Cyclacel Pharmaceuticals Company Profile (NASDAQ:CYCC)

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals logoCyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYCC
  • CUSIP:
Key Metrics:
  • Previous Close: $4.05
  • 50 Day Moving Average: $5.15
  • 200 Day Moving Average: $5.03
  • 52-Week Range: $3.05 - $9.72
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.72
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 3.36
Profitability:
  • Net Margins: -1,041.60%
  • Return on Equity: -87.61%
  • Return on Assets: -64.72%
Debt:
  • Current Ratio: 4.05%
  • Quick Ratio: 4.05%
Additional Links:
Companies Related to Cyclacel Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Cyclacel Pharmaceuticals (NASDAQ:CYCC) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Show:
DateFirmActionRatingPrice TargetDetails
8/12/2016HC WainwrightReiterated RatingBuyView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2017        
11/14/2016Q316($0.94)($0.86)ViewN/AView Earnings Details
5/11/2016Q116($0.09)$512.00 million$139.00 millionViewListenView Earnings Details
3/24/2016Q4($0.08)($0.10)ViewListenView Earnings Details
11/12/2015Q315($0.09)($0.08)ViewListenView Earnings Details
8/11/2015Q215($0.10)ViewListenView Earnings Details
5/12/2015Q115($0.25)($0.19)ViewListenView Earnings Details
3/24/2015Q414($0.26)($0.20)ViewN/AView Earnings Details
11/11/2014Q314($0.26)($0.22)ViewN/AView Earnings Details
8/12/2014Q214($0.30)($0.22)ViewN/AView Earnings Details
5/13/2014Q114($0.26)($0.25)ViewN/AView Earnings Details
3/25/2014Q413($0.33)($0.19)$0.09 million$0.30 millionViewN/AView Earnings Details
11/12/2013Q3($0.31)($0.31)ViewListenView Earnings Details
8/14/2013Q2 2013($0.10)$0.03 million$0.26 millionViewN/AView Earnings Details
5/13/2013Q1 2013($1.18)ViewN/AView Earnings Details
11/12/2012Q312($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Current Year EPS Consensus Estimate: $-3.89 EPS
Next Year EPS Consensus Estimate: $-5.48 EPS

Dividends

Current Dividend Information for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Annual Dividend:$0.15
Dividend Yield:3.83%
Payout Ratio:-2.80% (Based on Trailing 12 Months of Earnings)
-3.86% (Based on Current Year Consensus EPS Estimate)
-2.74% (Based on Next Year Consensus EPS Estimate)

Dividend History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/9/2016Annual$0.157/13/20167/17/20168/1/2016
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 18.78%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/20/2014Sam L BarkerDirectorBuy3,100$3.00$9,300.00View SEC Filing  
5/21/2013Lloyd SemsDirectorBuy33,333$3.00$99,999.00View SEC Filing  
5/21/2013Paul McbarronCFOBuy12,948$3.03$39,232.44View SEC Filing  
5/21/2013Spiro George RombotisInsiderBuy100,000$3.00$300,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
DateHeadline
investopedia.com logoCyclacel Plunges on Leukemia Drug Failure (CYCC) (NASDAQ:CYCC)
www.investopedia.com - February 24 at 12:00 PM
investopedia.com logoCyclacel Tanks on Leukemia Drug Failure (NASDAQ:CYCC)
www.investopedia.com - February 24 at 12:00 PM
streetinsider.com logoCyclacel Pharma (CYCC) Pivotal Phase 3 SEAMLESS Study in Elderly Patients With AML Doesn't Meet Primary Endpoint (NASDAQ:CYCC)
www.streetinsider.com - February 23 at 9:39 PM
News IconWhy Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Shares Are Trading down 19%? (NASDAQ:CYCC)
stockmarketdaily.co - February 23 at 9:39 PM
4-traders.com logoCyclacel Pharmaceuticals : CYCC) Tumbles on Failed Tests (NASDAQ:CYCC)
www.4-traders.com - February 23 at 9:39 PM
us.rd.yahoo.com logo6:57 am Cyclacel Pharma announces its Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia did not meet its primary endpoint (NASDAQ:CYCC)
us.rd.yahoo.com - February 23 at 9:39 PM
us.rd.yahoo.com logoCyclacel's leukemia drug for elderly patients fails in key study (NASDAQ:CYCC)
us.rd.yahoo.com - February 23 at 9:39 PM
marketwatch.com logoCyclacel's stock plunges after disappointing trial results of its cancer treatment (NASDAQ:CYCC)
us.rd.yahoo.com - February 23 at 9:39 PM
biz.yahoo.com logoCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CYCC)
us.rd.yahoo.com - February 23 at 9:39 PM
News IconStock in Review: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - Benton Bulletin (NASDAQ:CYCC)
bentonbulletin.com - February 23 at 4:37 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Tesla, L Brands, Nvidia, Cyclacel - Nasdaq (NASDAQ:CYCC)
www.nasdaq.com - February 23 at 4:37 PM
nasdaq.com logoMid-Day Market Update: AXT Rises After Strong Q4 Results; Cyclacel Pharma Shares Tumble - Nasdaq (NASDAQ:CYCC)
www.nasdaq.com - February 23 at 4:37 PM
seekingalpha.com logoCyclacel Pharmaceuticals (CYCC) Presents at 19th Annual BIO CEO & Investor Conference (NASDAQ:CYCC)
seekingalpha.com - February 14 at 5:26 PM
realistinvestor.com logoCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) EPS Projection At $-0.89 - RealistInvestor.com (NASDAQ:CYCC)
www.realistinvestor.com - February 13 at 5:20 PM
investornewswire.com logoCan Shares Of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Hit $60? - Investor Newswire (NASDAQ:CYCC)
www.investornewswire.com - February 11 at 9:44 PM
News IconTechnical Toolbox: Investor Focus on Cyclacel Pharmaceuticals Inc. (CYCC) - Sherwood Daily (NASDAQ:CYCC)
sherwooddaily.com - February 4 at 4:50 PM
News IconLooking at Moving Averages for Cyclacel Pharmaceuticals Inc. (CYCC) - Sherwood Daily (NASDAQ:CYCC)
sherwooddaily.com - February 2 at 5:01 PM
News IconTechnical Study: Following Indicators for Cyclacel Pharmaceuticals Inc. (CYCC) - Sherwood Daily (NASDAQ:CYCC)
sherwooddaily.com - February 1 at 10:06 PM
News IconInvestor Arena: Keeping an Eye on Cyclacel Pharmaceuticals Inc. (CYCC) - Sherwood Daily (NASDAQ:CYCC)
sherwooddaily.com - February 1 at 3:17 AM
News IconAre There Catalysts to Propel This Stock Forward: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - Prospect Journal (NASDAQ:CYCC)
prospectjournal.com - January 30 at 10:33 PM
News IconOff To a Slow Start in The New Year, Stock Looks For a Turnaround: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - Aiken Advocate (NASDAQ:CYCC)
aikenadvocate.com - January 29 at 2:53 AM
News IconMeasuring the Levels on Shares of Cyclacel Pharmaceuticals Inc. (CYCC) - Sherwood Daily (NASDAQ:CYCC)
sherwooddaily.com - January 27 at 11:09 PM
News IconWatching the Technicals on Shares of Cyclacel Pharmaceuticals Inc. (CYCC) - Sherwood Daily (NASDAQ:CYCC)
sherwooddaily.com - January 26 at 5:48 PM
News IconQuarterly EPS Of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Set At $-0.89 - Stock Observer (NASDAQ:CYCC)
www.thestockobserver.com - January 26 at 5:48 PM
capitalcube.com logoETFs with exposure to Cyclacel Pharmaceuticals, Inc. : January 19, 2017 (NASDAQ:CYCC)
www.capitalcube.com - January 19 at 5:53 PM
News IconGrowth Story Unfolding for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - Prospect Journal (NASDAQ:CYCC)
prospectjournal.com - January 17 at 8:35 AM
investornewswire.com logoCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Strong Sell Recommendations At {RATING_CNT_STRONG_SELLS ... - Investor Newswire (NASDAQ:CYCC)
www.investornewswire.com - January 14 at 9:41 PM
News IconCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Quarterly EPS Set At $-0.89 - Stock Observer (NASDAQ:CYCC)
www.thestockobserver.com - January 11 at 10:08 PM
realistinvestor.com logoCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) EPS Estimate At $-0.89 - RealistInvestor.com (NASDAQ:CYCC)
www.realistinvestor.com - January 10 at 2:29 AM
News IconBearish Target Of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At $60 - Stock Observer (NASDAQ:CYCC)
www.thestockobserver.com - January 9 at 2:35 AM
News IconQuarterly EPS Of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At $-0.89 - Stock Observer (NASDAQ:CYCC)
www.thestockobserver.com - January 5 at 3:47 AM
News IconDaily Sentiment Score Of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At -0.29 - Stock Observer (NASDAQ:CYCC)
www.thestockobserver.com - December 31 at 4:40 PM
investornewswire.com logoCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Strong Buy Recommendations At 1 - Investor Newswire (NASDAQ:CYCC)
www.investornewswire.com - December 31 at 4:40 PM
News IconAnalytical Approach on Price Target Estimates: Mast Therapeutics Inc (NYSEMKT:MSTX) (NASDAQ:CYCC)
diariocatolico.net - December 30 at 10:02 PM
News IconGuilty verdict in missing Maui pregnant woman's death (NASDAQ:CYCC)
vouxmagazine.com - December 29 at 10:03 PM
capitalcube.com logoETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 29, 2016 (NASDAQ:CYCC)
www.capitalcube.com - December 29 at 5:01 PM
capitalcube.com logoETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 29, 2016 (NASDAQ:CYCC)
www.capitalcube.com - December 29 at 5:01 PM
News IconAnthera Pharmaceuticals (ANTH) Crashes on Failed Drug Trial; Cyclacel Pharmaceuticals (CYCC) Takes Upward ... - Galaxy Stocks (press release) (registration) (NASDAQ:CYCC)
galaxystocks.com - December 28 at 4:39 PM
News IconStock in Spotlight: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Nabors Industries Ltd. (NYSE:NBR) - The Newburgh Press (NASDAQ:CYCC)
newburghpress.com - December 28 at 4:39 PM
News IconAnthera Pharmaceuticals (ANTH) Crashes on Failed Drug Trial; Cyclacel Pharmaceuticals (CYCC) Takes Upward Bounce (NASDAQ:CYCC)
galaxystocks.com - December 28 at 12:00 PM
streetinsider.com logoUnusual 11 Mid-Day Movers 12/27: (MBRX) (CYCC) (RADA) Higher; (ELGX) (SGEN) (GSAT) Lower (more...) (NASDAQ:CYCC)
www.streetinsider.com - December 27 at 4:51 PM
News IconCyclacel Pharmaceuticals, Inc. (CYCC) Updated Broker Ratings - NewsDen (NASDAQ:CYCC)
newsden.net - December 24 at 4:33 PM
investornewswire.com logoCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:CYCC)
www.investornewswire.com - December 24 at 4:33 PM
marketexclusive.com logoCYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Files An 8-K Departure of Directors or Certain Officers ... - Market Exclusive (NASDAQ:CYCC)
marketexclusive.com - December 24 at 2:54 AM
News IconReviewing the Levels for Cyclacel Pharmaceuticals, Inc. (NASDAQ ... - Wall Street Beacon (NASDAQ:CYCC)
wsbeacon.com - December 23 at 2:52 AM
4-traders.com logoCYCLACEL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:CYCC)
www.4-traders.com - December 22 at 4:50 PM
biz.yahoo.com logoCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CYCC)
biz.yahoo.com - December 22 at 4:50 PM
News IconNumbers in Focus for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - Wall Street Beacon (NASDAQ:CYCC)
wsbeacon.com - December 21 at 3:24 AM
realistinvestor.com logoCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) EPS Prediction At $-0.89 - RealistInvestor.com (NASDAQ:CYCC)
www.realistinvestor.com - December 20 at 10:24 PM
investornewswire.com logoStrong Sell Recommendations Of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0 - Investor Newswire (NASDAQ:CYCC)
www.investornewswire.com - December 19 at 2:44 AM

Social

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

How often does Cyclacel Pharmaceuticals pay dividends? What is the dividend yield for Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals declared an annual dividend on Thursday, June 9th. Stockholders of record on Sunday, July 17th will be paid a dividend of $0.15 per share on Monday, August 1st. The ex-dividend date of this dividend is Wednesday, July 13th.

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals's stock reverse split on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

When will Cyclacel Pharmaceuticals announce their earnings?

Cyclacel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 22nd 2017.

How do I buy Cyclacel Pharmaceuticals stock?

Shares of Cyclacel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cyclacel Pharmaceuticals stock cost?

One share of Cyclacel Pharmaceuticals stock can currently be purchased for approximately $3.92.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Earnings History Chart

Earnings by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Dividend History Chart

Dividend Payments by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Last Updated on 2/24/2017 by MarketBeat.com Staff